Sexually transmitted diseases in mothers of neonates with congenital cytomegalovirus infection
Article Abstract:
Cytomegalovirus (CMV) is the most common viral infection that is inherited at birth. It is estimated that one percent of all infants are infected with CMV when they are born. CMV infection damages vision, hearing, nerves and intellectual ability in 10 to 20 percent of the infants who become infected. To reduce the incidence (number of new cases) of CMV infection in newborns, methods of preventing CMV infection in women are needed. CMV is transmitted during sexual contact with an infected partner. This article describes the results of a study designed to identify risk factors associated with maternal CMV infection and passing the infection to an infant at birth. The study included 175 mothers who had babies with CMV infections. Most of the women (84 percent) were black and from low income families. Almost 90 percent of the women received prenatal care. Women who had other sexually transmitted diseases, such as gonorrhea and trichomoniasis (a type of vaginal infection), were two times more likely to give birth to a baby with CMV infection. Women who were poor, unmarried and young were four times more likely to give birth to a baby infected with CMV than women who were married, older and from higher income families. These results suggest that women who have sexually transmitted diseases, are young, unmarried and poor, have a greater risk of having a baby with CMV infection. (Consumer Summary produced by Reliance Medical Information, Inc.)
Publication Name: Journal of Infectious Diseases
Subject: Health
ISSN: 0022-1899
Year: 1991
User Contributions:
Comment about this article or add new information about this topic:
The outcome of congenital cytomegalovirus infection in relation to maternal antibody status
Article Abstract:
Pregnant women who have had recurrent cytomegalovirus (CMV) infections produce antibodies that may protect their baby from developing CMV infection after birth. Congenital CMV infections can cause hearing loss, eye diseases, mental retardation and neurological damage. Of 197 infants with congenital CMV infections, 132 had mothers who were became infected during the pregnancy (primary infection), and 65 had mothers who had been infected before the pregnancy (recurrent infection). Eighteen percent of the infants whose mothers had a primary infection had symptoms of congenital CMV infection at birth compared to none of the infants whose mothers had recurrent infections. At approximately four-and-a-half years of age, 25% of the children in the primary infection group had a complication of CMV infection, but only eight percent of the children in the recurrent infection group were affected. Vaccinating all women of childbearing age against CMV could prevent 6,000 congenital CMV infections each year.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1992
User Contributions:
Comment about this article or add new information about this topic:
Intrauterine transmission of cytomegalovirus to infants of women with preceonceptional immunity
Article Abstract:
Pregnant women who are immune to a particular type of cytomegalovirus can still transmit cytomegalovirus infection to their baby if they become infected with a different type. Babies who contract cytomegalovirus from their mothers at birth can develop brain damage and hearing loss.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Future directions in the management of cytomegalovirus infections
- Abstracts: Predictors of morbidity and mortality in neonates with herpes simplex virus infections. A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection
- Abstracts: Pivotal role of early and sustained infarct vessel patency in patients with acute myocardial infarction. Intracranial hemorrhage after use of tissue plasminogen activator for coronary thrombolysis
- Abstracts: Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection
- Abstracts: A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection